Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 525 of 885 entries
View as:

A Pharmacokinetic Study to Evaluate the Dose-Proportionality of Tramadol (ULTRAM) Extended-Release (ER) in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT01800682 Org: User:
Start: 07/31/11 End: 09/30/11 Due: 09/30/12

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02316106 Org: User:
Start: 05/20/15 End: 06/03/24 Due: 06/03/25

A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain

Phase: N/A Priority: Normal
NCT ID: NCT03089918 Org: User:
Start: 05/17/17 End: 08/24/18 Due: 08/24/19

A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04816513 Org: User:
Start: 04/14/21 End: 01/26/22 Due: 01/26/23

A Study of JNJ-69095897 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04920578 Org: User:
Start: 06/16/21 End: 02/27/23 Due: 02/27/24

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01962532 Org: User:
Start: 08/21/13 End: 01/28/16 Due: 01/28/17

A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)

Phase: N/A Priority: Normal
NCT ID: NCT05112952 Org: User:
Start: 11/30/21 End: 07/11/22 Due: 07/11/23

A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04655807 Org: User:
Start: 03/03/21 End: 09/04/23 Due: 09/04/24

A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05029921 Org: User:
Start: 12/10/21 End: 08/22/25 Due: 08/22/26

A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Phase: N/A Priority: Normal
NCT ID: NCT02606084 Org: User:
Start: 12/04/15 End: 02/02/18 Due: 02/02/19

A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

Phase: N/A Priority: Normal
NCT ID: NCT05268497 Org: User:
Start: 09/01/22 End: 06/07/23 Due: 06/07/24

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04223349 Org: User:
Start: 01/10/20 End: 04/08/20 Due: 04/08/21

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Phase: N/A Priority: Normal
NCT ID: NCT03842189 Org: User:
Start: 04/05/18 End: 08/05/24 Due: 08/05/25

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02699606 Org: User:
Start: 07/08/16 End: 03/15/24 Due: 03/15/25

An Epidemiology Study of Treatment Resistant Depression in the United States (US)

Phase: N/A Priority: Normal
NCT ID: NCT03109002 Org: User:
Start: 01/15/17 End: 05/18/17 Due: 05/18/18

A Study of JNJ-67835989 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04844411 Org: User:
Start: 04/27/21 End: 05/18/22 Due: 05/18/23

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03375697 Org: User:
Start: 12/22/17 End: 12/16/19 Due: 12/16/20

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03990519 Org: User:
Start: 06/24/19 End: 02/19/20 Due: 02/19/21

A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men

Phase: N/A Priority: Normal
NCT ID: NCT03693391 Org: User:
Start: 10/17/18 End: 03/13/19 Due: 03/13/20

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01615029 Org: User:
Start: 06/26/12 End: 10/23/24 Due: 10/23/25

A Study in a Human Laboratory Model of Smoking Behavior

Phase: N/A Priority: Normal
NCT ID: NCT02641028 Org: User:
Start: 12/31/15 End: 12/31/16 Due: 12/31/17

A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants

Phase: N/A Priority: Normal
NCT ID: NCT04185051 Org: User:
Start: 12/17/19 End: 05/05/21 Due: 05/05/22

A Study of 14C JNJ-67953964 in Healthy Adult Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT05197062 Org: User:
Start: 01/14/22 End: 03/02/22 Due: 03/02/23

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05307692 Org: User:
Start: 05/19/22 End: 11/10/23 Due: 11/10/24

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT02902601 Org: User:
Start: 10/17/16 End: 06/07/17 Due: 06/07/18